Hi Bluegoose, re your comment "1 or more MIN share for every ESS...

First 87 Last

Share
Profile

Follow
Names little

19,346 Posts.

1474

17/04/23

05:11

Post #: 67302444
Share

Originally posted by Bluegoose: ↑

It will be an interesting week ahead.

I'm trying to anticipate what may happen but it seems difficult.

If the Scheme meeting is set to go ahead on Thursday (can they stop it beforehand??) even though it's a dead duck, does that give MIN an opportunity to make a T/O offer and keep acquiring more shares at around their offer price (whatever that may be) and get to say 30% of the company by Thursday?.

Or are they content to sit on their near 20% and wait for IGO to make another move, or walk away.

As I've said, I'm leaning towards thinking MIN will be making a bid in the next couple of weeks. It would be nice if it's Monday so we all know what's going on but we may need to have some patience.

Whatever the strategy of both IGO and MIN, I very much doubt we are ever going below 50 cents again (sorry to inform you Timmy!!), and I would expect things to end up well north of 60 cents, and preferably 80+ cents (1or more MIN share for every ESS share).

I've been kicking myself for not owning LTR along the way and seeing the fun they are having with ALB offers.

But now we get to be part of a fun game seeing where this all ends up and hopefully make a lot more cash out of it than Friday's close.

I'll be watching the announcements tomorrow with excitement and getting ready to celebrate if we have a nice win in due course as it's been tough to stay the course with ESS.

Expand

Hi Bluegoose, re your comment "1 or more MIN share for every ESS share"

Would be nice but not likely with MIN shares trading at nearly $80.

ESS Price at posting: 58.0¢ Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

'Not possible' to port renewable gas: ACCC takes AGN to court

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 87 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Hi Bluegoose, re your comment "1 or more MIN share for every ESS...

Top Stories

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

'Not possible' to port renewable gas: ACCC takes AGN to court

Boss extends June win streak with boosted Alta Mesa extraction rates

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Australia’s gas crisis is here – and dying coal plants aren’t helping

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News